Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

July 30, 2028

Conditions
Diffuse Large B-cell LymphomaRelapsed and Refractory
Interventions
DRUG

Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab

"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."

Trial Locations (1)

361000

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER